Pharma & Biotech Insights, Interviews & Features
Generics
8 November 2024 8 November 2024
Today's issue
Refine Search
Generics
Russian pharmaceutical companies will receive additional subsidies from the state for the development of analogues of foreign drugs, as part of the current state plans for the reduction of import dependence in the country’s pharmaceutical sector, The Pharma Letter’s local correspondent reports. 9 June 2023
Pharmaceutical
GLP1 receptor agonists (GLP1RA) are known as diabetes treatments, but recently they have also doubled as the new generation drugs for overweight/obesity. 5 June 2023
Pharmaceutical
As the crowds descend on Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO), The Pharma Letter interviews Eisai chief medical officer Kirk Shepard about his firm’s progress in oncology. 1 June 2023
Pharmaceutical
This year’s meeting of the American Society of Clinical Oncology (ASCO) kicks off on Friday, with the highly anticipated plenary session taking place on Sunday. 31 May 2023
Generics
Even as Tariq Ahmad, UK Minister of State for Foreign, Commonwealth and Development Affairs and India's External Affairs Minister S Jaishankar held talks in Delhi on Monday, and discussed the India-UK Free Trade Agreement (FTA), Indian pharmaceutical companies have joined forces to urge the government to maintain a strong stance on the Patents Act as it negotiates FTAs with key global partners. 30 May 2023
Biotechnology
Earlier this month, UK biotech Bicycle Therapeutics entered a strategic collaboration with Germany’s Bayer. 26 May 2023
Generics
In an effort to decrease pharmaceutical companies profiteering, India's National Pharmaceutical Pricing Authority (NPPA) has said the ceiling price of off-patent pharmaceuticals will be slashed by 50%. 26 May 2023
Biotechnology
Ichthyosis is a heterogenous group of disorders characterized by dry, itchy skin that appears scaly and rough like fish scales.1,2 The first case of ichthyosis was described 24 May 2023
Pharmaceutical
The US Food and Drug Administration (FDA) released its final guidance on risk-based monitoring of clinical investigations in April 2023. 23 May 2023
Generics
Leading Russian drugmakers have called on the state to simplify the launch of their generics to the domestic market by reducing the number of so-called evergreen patents of global majors, reports The Pharma Letter’s local correspondent. 22 May 2023
Generics
German pharma major Bayer has filed a lawsuit against the Russian manufacturer of generic drugs Medisorb, The Pharma Letter’s local correspondent reports. 19 May 2023
Pharmaceutical
An Expert View from George Magrath, an ophthalmologist and chief executive of USA-based biopharma company Lexitas. 19 May 2023
Pharmaceutical
A feature on the US drugmaker's drive to replace declining sales of the world's biggest-selling drug. 18 May 2023
Generics
India's pharmaceutical industry captains have voiced their plea to the government, urging an expansion of the bulk drugs park scheme beyond its current scope. 16 May 2023
Pharmaceutical
The Russian government will consider the allocation up to 48 billion roubles ($625 million) in public procurements of anti-HIV drugs this year, The Pharma Letter’s local correspondent reports. 12 May 2023
Pharmaceutical
The life sciences industry has always been subjected to transparency requirements. To help avoid compliance violations that may lead to penalties, many life science organizations have ramped up their efforts to collect compliance data and streamline the reporting process. 10 May 2023
Biotechnology
Risk control was a major topic at the DJSeedin innovation partnering event held on last month in Shanghai as Chinese biotechs are seeking more licensing deals and partnerships to survive in tmpetition in China. 4 May 2023
Biosimilars
Several factors are contributing to the growth of India's biotech industry, including increased government support, favourable regulatory policies, and a vibrant start-up ecosystem. A $500 billion target is in the works for the country's bioeconomy by 2047, the year in which it will celebrate its 100th anniversary of independence, reports The Pharma Letter’s India correspondent. 3 May 2023
Pharmaceutical
Russians have significantly increased drugs purchases from other countries amid the ever-declining domestic range and the ever-growing isolation of the country in the international arena, reports The Pharma Letter’s local correspondent. 2 May 2023
Pharmaceutical
Members of the Russian Parliament have not ruled out the possibility of the beginning forced transfer of licenses for the production of innovative drugs in Russia in case of exodus of their producers from the local market. 2 May 2023
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 7 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 31 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences. 20 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze